Metformin in Heart Failure
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
We recently learned of an important change in the prescribing information for metformin, previously contraindicated in patients with type 2 diabetes accompanied by heart failure (HF) requiring pharmacological therapy. The contraindication was introduced to the label soon after the drug's U.S. release, when case reports emerged of HF patients taking metformin who developed lactic acidosis. It was never clear, however, whether either the HF or the medication were contributing factors. Subsequent analyses revealed a miniscule risk of lactic acidosis associated with metformin …
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Restrictions to use of metformin in people with medically treated heart failure were removed by the FDA in 2006 (289).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [289]
In the citing paper
“Restrictions to use of metformin in people with medically treated heart failure were removed by the FDA in 2006 (221).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [221]
Citations
Cites
Masoudi, F. A., Inzucchi, S. E., Wang, Y., Havranek, E. P., Foody, J. M., & Krumholz, H. M. (2005) · Circulation · doi:10.1161/01.cir.0000154542.13412.b1 · Cited by 458
Self-citationImproved clinical outcomes associated with metformin in patients with diabetes and heart failure
Eurich, D. T., Majumdar, S. R., McAlister, F. A., Tsuyuki, R. T., & Johnson, J. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.10.2345 · Cited by 419 · cited 1×
“In 2005, two studies (2,3) suggested that metformin was safe and may also provide advantages in the very patients in whom the drug was not to be used.”
BackgroundThe Phantom of Lactic Acidosis due to Metformin in Patients With Diabetes
Misbin, R. I. (2004) · Diabetes Care · doi:10.2337/diacare.27.7.1791 · Cited by 200
Diabetes Mellitus and Heart Failure: Epidemiology, Mechanisms, and Pharmacotherapy
Masoudi, F. A., & Inzucchi, S. E. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.013 · Cited by 97
Self-citation
Cited by
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s010 · Cited by 869
Bozkurt, B., Aguilar, D., Deswal, A., Dunbar, S. B., Francis, G. S., Horwich, T., Jessup, M., Kosiborod, M., Pritchett, A. M., Ramasubbu, K., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000450 · Cited by 522
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s010 · Cited by 495
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s010 · Cited by 487
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Das, S. R., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s010 · Cited by 486
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Das, S. R., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s010 · Cited by 465
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Das, S. R., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s010 · Cited by 438
Gundewar, S., Calvert, J. W., Jha, S., Toedt-Pingel, I., Yong Ji, S., Nunez, D., Ramachandran, A., Anaya-Cisneros, M., Tian, R., & Lefer, D. J. (2009) · Circulation Research · doi:10.1161/circresaha.108.190918 · Cited by 423
Eurich, D. T., Weir, D. L., Majumdar, S. R., Tsuyuki, R. T., Johnson, J. A., Tjosvold, L., Vanderloo, S. E., & McAlister, F. A. (2013) · Circulation: Heart Failure · doi:10.1161/circheartfailure.112.000162 · Cited by 341
“Historically, metformin had been considered absolutely contraindicated in patients with HF attributable to concerns about lactic acidosis.(9) However, both the US Food and Drug Administration (2006) and Health Canada (2010) have removed the absolute HF contraindication from metformin (although strong warnings persist)…”
BackgroundNesti, L., & Natali, A. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.04.009 · Cited by 211
Sarma, S., Mentz, R. J., Kwasny, M. J., Fought, A. J., Huffman, M., Subacius, H., Nodari, S., Konstam, M., Swedberg, K., Maggioni, A. P., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs153 · Cited by 202
Metformin Uniquely Prevents Thrombosis by Inhibiting Platelet Activation and mtDNA Release
Xin, G., Wei, Z., Ji, C., Zheng, H., Gu, J., Ma, L., Huang, W., Morris-Natschke, S. L., Yeh, J.-L., Zhang, R., et al. (2016) · Scientific Reports · doi:10.1038/srep36222 · Cited by 125
Metformin, beyond an insulin sensitizer, targeting heart and pancreatic β cells
Yang, X., Xu, Z., Zhang, C., Cai, Z., & Zhang, J. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.09.019 · Cited by 121
Metformin Therapy and Outcomes in Patients With Advanced Systolic Heart Failure and Diabetes
Shah, D. D., Fonarow, G. C., & Horwich, T. B. (2010) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2009.10.022 · Cited by 100
Cardioprotection by Metformin: Beneficial Effects Beyond Glucose Reduction
Varjabedian, L., Bourji, M., Pourafkari, L., & Nader, N. D. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0266-3 · Cited by 90
AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases
Lu, Q., Li, X., Liu, J., Sun, X., Rousselle, T., Ren, D., Tong, N., & Li, J. (2019) · Bioscience Reports · doi:10.1042/bsr20181995 · Cited by 69
Larsen, A. H., Jessen, N., Nørrelund, H., Tolbod, L. P., Harms, H. J., Feddersen, S., Nielsen, F., Brøsen, K., Hansson, N. H., Frøkiær, J., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1656 · Cited by 70
Metformin: Nonglycemic Effects and Potential Novel Indications
Anabtawi, A., & Miles, J. M. (2016) · Endocrine Practice · doi:10.4158/ep151145.ra · Cited by 65
Metformin and heart failure: never say never again
Papanas, N., Maltezos, E., & Mikhailidis, D. P. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.638283 · Cited by 39
Prescribing metformin in type 2 diabetes with a contraindication: prevalence and outcome
Pongwecharak, J., Tengmeesri, N., Malanusorn, N., Panthong, M., & Pawangkapin, N. (2009) · Pharmacy World & Science · doi:10.1007/s11096-009-9303-2 · Cited by 38
Hormone replacement therapy in heart failure
Arcopinto, M., Salzano, A., Isgaard, J., & Cittadini, A. (2015) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000166 · Cited by 43
“However, both are contraindicated or not recommended in CHF patients: thiazolidinediones are unsafe in CHF patients because of the increased renal sodium reabsorption and vascular permeability resulting in increased incidence of CHF [56], while metformin contraindication in CHF is being revised [57] after new evidence…”
BackgroundRegeneration and Assessment of the Endothelial Glycocalyx To Address Cardiovascular Disease
Banerjee, S., Mwangi, J. G., Stanley, T. K., Mitra, R., & Ebong, E. E. (2021) · Industrial & Engineering Chemistry Research · doi:10.1021/acs.iecr.1c03074 · Cited by 45
Harrington, J. L., de Albuquerque Rocha, N., Patel, K. V., Verma, S., & McGuire, D. K. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1035-z · Cited by 32
Self-citationBeneš, J., Kotrč, M., Kroupova, K., Wohlfahrt, P., Kovar, J., Franeková, J., Hegarová, M., Hošková, L., Hošková, E., Pelikánová, T., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-17327-4 · Cited by 33
Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus
Sharma, A., Cooper, L. B., Fiuzat, M., Mentz, R. J., Ferreira, J. P., Butler, J., FITCHETT, D. H., Moses, A. C., O’Connor, C. J., & Zannad, F. M. (2018) · JACC Heart Failure · doi:10.1016/j.jchf.2018.05.020 · Cited by 30
Knežević, D., Ćurko‐Cofek, B., Batinac, T., Laškarin, G., Rakić, M., Šoštarič, M., Zdravković, M., Šustić, A., Tokmadžić, V. S., & Batičić, L. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10050213 · Cited by 35
Mbara, K. C., Mato, P. E. M., Driver, C., Nzuza, S., Mkhombo, N. T., Gcwensa, S. K., Mcobothi, E. N., & Owira, P. M. O. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173934 · Cited by 36
Onoue, T., Kang, Y., Lefebvre, B., Smith, A. M., Denduluri, S., Carver, J. R., Fradley, M. G., Chittams, J. L., & Scherrer‐Crosbie, M. (2023) · JACC CardioOncology · doi:10.1016/j.jaccao.2023.05.013 · Cited by 17
Komaru, Y., Takeuchi, T., Suzuki, L., Asano, T., & Urayama, K. Y. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.107511 · Cited by 18
Staszewsky, L. I., Baviera, M., Tettamanti, M., Colacioppo, P., Robusto, F., D'Ettorre, A., Lepore, V. L., Fortino, I., Bisceglia, L., Attolini, E., et al. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002708 · Cited by 17
Roussel, R., Hadjadj, S., Pasquet, B., Wilson, P. W. F., Smith, S. C., Goto, S., Tubach, F., Marre, M., Porath, A., Krempf, M., et al. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.04.019 · Cited by 12
Metformin Use in Patients With Historical Contraindications
Lipska, K. J. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2712 · Cited by 14
“However, in 2006, the FDA eliminated the heart failure warning in response to 2 large observational studies (3) that suggested that metformin is safe and may be beneficial in patients with compensated heart failure.”
BackgroundManagement of type 2 diabetes in patients with heart failure
Aguilar, D. A. (2008) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-008-0039-4 · Cited by 9
METFORMIN: NON-GLYCEMIC EFFECTS AND POTENTIAL NOVEL INDICATIONS.
Anabtawi, A., & Miles, J. (2016) · Endocrine Practice · doi:10.4158/ep151145.rar · Cited by 10
“Because of the availability of new information regarding the safety of metformin in patients with heart failure, the contraindication was subsequently withdrawn by the Food and Drug Administration (72).”
BackgroundComoglio, R. H., & Vidal, X. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.11.002 · Cited by 13
Treating Disease Mechanisms in Patients With Heart Failure and Diabetes Mellitus
Trang, A., & Aguilar, D. A. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0371-7 · Cited by 28
Metformin Use in Decompensated Heart Failure
Boyd, A., & Nawarskas, J. J. (2008) · Cardiology in Review · doi:10.1097/crd.0b013e3181846c53 · Cited by 11
“In 2005, the US Food and Drug Administration advised metformin manufacturers to amend the package insert to remove the contraindication for metformin use in patients with HF primarily due to the results of 2 cohort studies.(24) Eurich et al(25) followed 1833 incident HF cases who were treated with sulfonylurea monothe…”
BackgroundHuang, W., & Zhao, R. (2024) · Endocrine · doi:10.1007/s12020-024-04025-6 · Cited by 9
“However, in 2006, the FDA rescinded the contra-indication against Met ’ s use in patients with HF, a decision in fl uenced by two observational studies [5].”
Metformin: from mechanisms of action to advanced clinical use
Janić, M., Volčanšek, Š., Lunder, M., & Janež, A. (2017) · doi:10.6016/slovmedjour.v86i3-4.1503 · Cited by 7
“Zaradi vse več dokazov, da pri bolnikih s srčnim popuščanjem in sladkorno boleznijo metformin zelo redko povzroča laktacidozo (102), je FDA leta 2006 umaknila srčno popuščanje kot absolutno kontraindikacijo za zdravljenje z metforminom (106).”
BackgroundDose modification of antidiabetic agents in patients with type 2 diabetes mellitus and heart failure
Sharma, D., Asirvatham, A. J., & Singh, P. (2017) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_442_16 · Cited by 8
“Formally, metformin was contraindicated in patients with heart failure as it causes lactic acidosis.[41,42] However, a recent systematic review of observational studies witnessed that metformin compared to control group is associated with lower rate of all-cause mortality (23% vs.”
BackgroundTreatment Considerations for Diabetes: A Pharmacist’s Guide to Improving Care in the Elderly
Nicholas, A., Nadeau, D. A., & Johnson, A. C. L. (2009) · Journal of Pharmacy Practice · doi:10.1177/0897190009333160 · Cited by 2
“The FDA no longer requires the brand named product’s (Glucophage) manufacturer, Bristol Myers Squibb, to list patient age of 80 years or older and history of congestive heart failure requiring any pharmacologic therapy as absolute contraindications to metformin’s use.(63,64)”
BackgroundIntersection Between Diabetes and Heart Failure: Is SGLT2i the “One Stone for Two Birds” Approach?
Zhang, Q., Kang, Y., Tang, S., & Yu, C. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01591-3 · Cited by 6
Metabolismo energético del corazón y sus proyecciones en el tratamiento de la insuficiencia cardíaca
Castro, P., Gabrielli, L., Verdejo, H., Greig, D. P., Mellado, R., Concepción, R., Sepúlveda, L., Vukasovic, J. L., GARCÍA, L., Pizarro, M., et al. (2010) · Revista médica de Chile · doi:10.4067/s0034-98872010000800014 · Cited by 3
Bajaj, N. S., & Vaduganathan, M. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1856 · Cited by 2
Approach to Chronic Kidney Disease in the Diabetic Patient
Afshinnia, F., & Brosius, F. C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-411602-3.00043-3 · Cited by 1
Rhee, E. (2021) · Journal of Korean Diabetes · doi:10.4093/jkd.2021.22.1.12 · Cited by 2
Thakkar, H. V., & Negishi, K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-64067-1.00028-0
Why Metformin Is so Important for Prevention and Therapy in Climacteric Women
Kuliczkowska-Płaksej, J., Milewicz, A., Brona, A., & Bolanowski, M. (2018) · ISGE series · doi:10.1007/978-3-319-63540-8_11
Metadata
- Authors
- Inzucchi, S. E., Masoudi, F. A., & McGuire, D. K.
- Affiliations
- Yale University (US)
- Denver Health Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2007-12-01
- Volume
- 30
- Issue
- 12
- Pages
- e129-e129
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2062092530
- Cited by
- 64
- References
- 0
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 3 · 2022: 6 · 2021: 6 · 2020: 4 · 2019: 4 · 2018: 5 · 2017: 6 · 2016: 6 · 2015: 2 · 2014: 2 · 2013: 1 · 2012: 4
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- metformin, heart failure, lactic acidosis, drug contraindications, prescribing information, type 2 diabetes, drug safety, risk-benefit assessment
- MeSH terms
- Aged, Diabetes Mellitus, Type 2, Female, Heart Failure, Humans, Hypoglycemic Agents, Male, Metformin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.